Company Overview and News

0
Zandu Realty to turn ex-date for merger

2018-05-22 thehindubusinessline
Shares of Zandu Realty will turn ex-date on Thursday for the proposed amalgamation with Emami Infrastructure. The latter will issue seven shares for every one share of ₹100 each held in Zandu Realty. Investors wishing to receive Emami shares need to own Zandu Realty shares by Wednesday, as the company has fixed May 25 as the record date. While the shares of Emami jumped 12.3 per cent to ₹278, those of Zandu gained 6.
533218 ZANDUREALT EMAMIINFRA PQRTY PETRONET 506720 532522

0
Zandu Realty Limited - Suspension of trading in equity shares

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZANDUREALT 506720

22
Market Live: Sensex in the red, rupee sinks 35 paise; BJP leads in Karnataka but away from half-way mark

2018-05-15 moneycontrol
Earnings: Pharma major Lupin has posted a loss of Rs 783.5 crore for the quarter ended March 2018, due to one-time loss of Rs 1,464.3 crore on Gavis Group acquisition.
PWQFY 539150 500325 EMAMIINFRA BHUSANSTL RELIANCE PNCINFRA 532810 539437 500470 IDFCBANK RIGD 500570 SNOWMAN TATAMOTORS 500055 RLNIY INDIGO IBN 532605 JBMA 538635 539448 PFC ICICIBANK 533218 ZANDUREALT TTST INDIANHUME TATASTEEL TATLY 532174 504741 506720 TTM

22
Market Live: Sensex off day#39;s high, midcaps weak; BJP leads in Karnataka but away from half-way mark

2018-05-15 moneycontrol
Market Update: The market lost more than 3/4th of its gains in afternoon trade. The BJP is likely to emerge as the single largest party in the Karnataka Assembly as it leads in 106 constituencies but is slightly away from its half-way mark.
PWQFY 500325 EMAMIINFRA BHUSANSTL RELIANCE 532810 539437 500470 IDFCBANK RIGD 507747 TTKHEALTH 500570 TATAMOTORS 500055 RLNIY INDIGO IBN 539448 PFC ICICIBANK 533218 ZANDUREALT TTST TATASTEEL TATLY 532174 506720 TTM

9
Market Live: Sensex, Nifty Bank off day#39;s high; BJP maintains lead in Karnataka

2018-05-15 moneycontrol
Market Outlook: VK Sharma, Head Private Client Group & Capital Market Strategy at HDFC Securities said going by the trends and the leads so far, with BJP emerging as a the single largest party, markets are relieved. Even if the Congress forms the Government with the help of the JDS, the markets won’t be perturbed.
533218 500470 ZANDUREALT TTST TATASTEEL TATLY EMAMIINFRA BHUSANSTL 507747 TTKHEALTH 506720 500055

0
Zandu Realty Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZANDUREALT 506720

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...